Solid Biosciences Inc. Finance Lease, Liability, Noncurrent
Solid Biosciences Inc. (SLDB) had Finance Lease, Liability, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:FinanceLeaseLiabilityNoncurrent · last filed 2025-03-06
- 2024-12-31: Finance Lease, Liability, Noncurrent $0.00.
- 2024-09-30: Finance Lease, Liability, Noncurrent $307.00K.
- 2024-06-30: Finance Lease, Liability, Noncurrent $953.00K.
- 2024-03-31: Finance Lease, Liability, Noncurrent $1.10M.
| Period end | Finance Lease, Liability, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2024-09-30 | $307.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $953.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.10M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.23M 10-K · filed 2025-03-06 |
| 2022-12-31 | $1.70M 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 |
| 2022-03-31 | $231.00K 10-Q · filed 2022-04-27 |
| 2021-12-31 | $293.00K 10-Q · filed 2022-11-10 |
| 2021-09-30 | $353.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $412.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $469.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $525.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $579.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $632.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $683.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $733.00K 10-K · filed 2021-03-15 |
| 2019-09-30 | $782.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $829.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $813.00K 10-Q · filed 2019-05-13 |
| 2018-12-31 | $859.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |